Clinical Trials Logo

Clinical Trial Summary

Endocopic remission rates of moderate to severe ulcerative colitis are low. Biologics including Vedolizumab, infliximab, and adalimumab are effective in induction and maintainence of ulcerative colitis. The role of 5-ASA in promoting a higher rate of endocsopic remission is unclear. We aim to evaluate the efficacy of combination of 5-ASA and biologics in treating ulcerative colitis.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05205603
Study type Interventional
Source Sixth Affiliated Hospital, Sun Yat-sen University
Contact Min Zhi
Phone 13825086505
Email [email protected]
Status Not yet recruiting
Phase Phase 4
Start date January 15, 2022
Completion date January 15, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Completed NCT03124121 - Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Phase 4
Withdrawn NCT04209556 - A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis Phase 2
Terminated NCT00061282 - Clotrimazole Enemas for Pouchitis in Children and Adults Phase 1/Phase 2
Recruiting NCT04398550 - SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis N/A
Recruiting NCT04857112 - Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis Phase 2
Recruiting NCT05051943 - A Prospective Observational Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Active, not recruiting NCT04033445 - A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis Phase 2/Phase 3
Recruiting NCT04767984 - Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis Phase 2
Active, not recruiting NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Completed NCT03760003 - Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis Phase 2
Recruiting NCT05287126 - A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis Phase 2
Not yet recruiting NCT05539625 - Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis Phase 2
Not yet recruiting NCT05507203 - ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 Phase 3
Not yet recruiting NCT05507216 - ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 Phase 3
Not yet recruiting NCT05507931 - Broccoli Sprouts for Mild Ulcerative Colitis N/A
Recruiting NCT02768974 - Open Label Study to Assess Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis Phase 2
Active, not recruiting NCT02914717 - The Belgian SMART Study Evaluating the Use of Golimumab for Ulcerative Colitis N/A
Completed NCT02888379 - Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis Phase 2
Active, not recruiting NCT02084550 - Amino Acids in Ileal Pouch-anal Anastomosis for Ulcerative Colitis N/A